A new method for recombinant adeno-associated virus vector delivery to murine diaphragm

Molecular Therapy

Volumn 9, Issue 3, 2004, Pages 458-463

  Mah, Cathryn ^a,b   Fraites Jr , Thomas J ^a   Cresawn, Kerry O ^a   Zolotukhin, Irene ^a,b   Lewis, Melissa A ^a,b   Byrne, Barry J ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b Department of Pediatrics ^*  (United States)

Author keywords

Acid glucosidase; Adeno associated virus; Diaphragm; Gene delivery; Glycogen storage disease type II; Pompe

Indexed keywords

BETA GALACTOSIDASE; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAPHRAGM; GEL; GENE TRANSFER; GENETIC TRANSDUCTION; IN VIVO STUDY; MOUSE; MYOPATHY; NONHUMAN; SEROTYPING; SOLUTION AND SOLUBILITY; TARGET CELL; TARGET ORGAN; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENO-ASSOCIATED VIRUS; MURINAE;

EID: 1642484383     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.01.006     Document Type: Review

References (35)

1. Petrof, B. J. (1998). Respiratory muscles as a target for adenovirus-mediated gene therapy. Eur. Respir. J. 11: 492-497.
2. Baranov, A., et al. (1999). Local and distant transfection of mdx muscle fibers with dystrophin and LacZ genes delivered in vivo by synthetic microspheres. Gene Ther. 6: 1406-1414.
3. Liu, F., Nishikawa, M., Clemens, P. R., and Huang, L. (2001). Transfer of full-length Dmd to the diaphragm muscle of Dmd(mdx/mdx) mice through systemic administration of plasmid DNA. Mol. Ther. 4: 45-51.
4. Buning, H., et al. (2003). Receptor targeting of adeno-associated virus vectors. Gene Ther. 10: 1142-1151.
5. Muller, O. J., et al. (2003). Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat. Biotechnol. 21: 1040-1046.
6. Perabo, L., et al. (2003). In vitro selection of viral vectors with modified tropism: The adeno-associated virus display. Mol. Ther. 8: 151-157.
7. Ponnazhagan, S., Mahendra, G., Kumar, S., Thompson, J. A., and Castillas, M., Jr. (2002). Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands. J. Virol. 76: 12900-12907.
8. Shi, W., Arnold, G. S., and Bartlett, J. S. (2001). Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum. Gene Ther. 12: 1697-1711.
9. Shi, W., and Bartlett, J. S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7: 515-525.
10. Wu, P., et al. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74: 8635-8647.
11. Muzyczka, N. (1992). Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol. 158: 97-129.
12. Kessler, P. D., et al. (1996). Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc. Natl. Acad. Sci. USA 93: 14082-14087.
13. Clark, K. R., Sferra, T. J., and Johnson, P. R. (1997). Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. Hum. Gene Ther. 8: 659-669.
14. Fisher, K. J., et al. (1997). Recombinant adeno-associated virus for muscle directed gene therapy. Nat. Med. 3: 306-312.
15. Gao, G. P., et al. (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA 99: 11854-11859.
16. Grimm, D., Kay, M. A., and Kleinschmidt, J. A. (2003). Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol. Ther. 7: 839-850.
17. Xiao, W., et al. (1999). Gene therapy vectors based on adeno-associated virus type 1. J. Virol. 73: 3994-4003.
18. Zolotukhin, S., et al. (2002). Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28: 158-167.
19. Rabinowitz, J. E., et al. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76: 791-801.
20. Fraites, T. J., Jr., et al. (2002). Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol. Ther. 5: 571-578.
21. Chao, H., Monahan, P. E., Liu, Y., Samulski, R. J., and Walsh, C. E. (2001). Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Mol. Ther. 4: 217-222.
22. Chao, H., et al. (2000). Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol. Ther. 2: 619-623.
23. Hauck, B., and Xiao, W. (2003). Characterization of tissue tropism determinants of adeno-associated virus type 1. J. Virol. 77: 2768-2774.
24. Raben, N., et al. (1998). Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J. Biol. Chem. 273: 19086-19092.
25. Moufarrej, N. A., and Bertorini, T. E. (1993). Respiratory insufficiency in adult-type acid maltase deficiency. South. Med. J. 86: 560-567.
26. March, K. L., Madison, J. E., and Trapnell, B. C. (1995). Pharmacokinetics of adenoviral vector-mediated gene delivery to vascular smooth muscle cells: Modulation by poloxamer 407 and implications for cardiovascular gene therapy. Hum. Gene Ther. 6: 41-53.
27. Van Belle, E., et al. (1998). Effects of poloxamer 407 on transfection time and percutaneous adenovirus-mediated gene transfer in native and stented vessels.Hum. Gene Ther. 9: 1013-1024.
28. Croyle, M. A., Cheng, X., and Wilson, J. M. (2001). Development of formulations that enhance physical stability of viral vectors for gene therapy. Gene Ther. 8: 1281-1290.
29. Seiler, M. P., et al. (2002). Thixotropic solutions enhance viral-mediated gene transfer to airway epithelia. Am. J. Respir. Cell Mol. Biol. 27: 133-140.
30. Mah, C., et al. (2002). Improved method of recombinant AAV2 delivery for systemic targeted gene therapy. Mol. Ther. 6: 106-112.
31. Stedman, H. H., et al. (1991). The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 352: 536-539.
32. Petrof, B. J., et al. (1995). Efficiency and functional consequences of adenovirus-mediated in vivo gene transfer to normal and dystrophic (mdx) mouse diaphragm. Am. J. Respir. Cell Mol. Biol. 13: 508-517.
33. Yang, L., et al. (1998). Adenovirus-mediated dystrophin minigene transfer improves muscle strength in adult dystrophic (MDX) mice. Gene Ther. 5: 369-379.
34. Sakamoto, M., et al. (2002). Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem. Biophys. Res. Commun. 293: 1265-1272.
35. Kawamoto, S., et al. (2003). AAV6 vectors promote efficient transduction and gene dissemination through myocardium in vivo. Mol. Ther. 7: S228.